Different game but it's the same question i ask in the life science space: why do the Roche, Novartis, Merck and Pfizers of the world not invest modest $10-20M sums in some of these cutting edge oncology et.al novel drugs and instead wait until the project is derisked past Phase II minimum (usually Phase III) and then pay $100-500M+?
Perhaps the answer is as simple as, they don't have to and even $100M is a drop in the ocean, giving them the luxury of being able to wait and the pharma with the greatest internal synergies can bid the highest price.
- Forums
- ASX - By Stock
- 4D-S Systems - A Closer look
Different game but it's the same question i ask in the life...
-
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)